Tags : Terminate

Helsinn and MEI Terminate its P-III Study of Pracinostat for

Shots: Interim analysis of the ongoing P-III study of pracinostat + azacitidine in patients with AML who are unfit to receive CT demonstrated that it was unlikely to meet its 1EPs of OS Based on the outcome of the interim analysis, the companies will discontinue the ongoing study as the decision is based on a […]Read More

EMD Serono and Pfizer to Terminate P-III JAVELIN Head and

Shots: The P-III JAVELIN Head and Neck 100 study involve assessing of Bavencio (avelumab) + CRT followed by avelumab maintenance vs CRT alone in 697 patients with previously untreated LA SCCHN The companies have accepted DMC’s recommendation to terminate the P-III JAVELIN Head and Neck 100 study as it did not meet its 1EPs i.e. […]Read More

Chugai and Sanofi to Terminate their Licensing Agreement for Tofogliflozin

Shots: Chugai and Sanofi terminate their 2012 licensing agreement, allowing Sanofi to transfer marketing rights of Apleway to Kowa as of Apr 01, 2020 with the anticipated transfer of marketing authorization in Jun’2020 In 2012, Chugai granted Kowa & Sanofi commercial rights of tofogliflozin 20mg under the brand name Deberza & Apleway respectively, following the […]Read More

Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane

Shots: In accordance with the expiration of the effective period of the co-marketing agreement, the companies will terminate their co-marketing agreement for Clexane SC Kit 2000 IU on Dec 31, 2019 In Jan’2008, Sanofi got manufacturing and marketing approval for Clexane SC Kit 2000 IU while Kaken initiated marketing and information service activities in Jul’2010 […]Read More

Tracon Terminates its P-III TAPPAS Trial of TRC105 (carotuximab) +

Shots: The termination is based on the recommendation of the Independent Data Monitoring Committee (IDMC) following its review of P-III TAPPAS trials assessing TRC105 (carotuximab) + Votrient (pazopanib) vs Votrient in 340 patients with advanced or metastatic angiosarcoma The P-III TAPPAS trial showed disappointing results and demonstrated no efficacy in patients with advanced or metastatic […]Read More

Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for

Shots: The termination is based on P-III EMERGE and ENGAGE study results assessing Aducanumab vs PBO in ~ 3,200 patients with mild cognitive impairment due to Alzheimer’s disease and dementia across the world The termination is due to its inability to meet 1EPs resulted in the loss of ~$18B to Biogen. Biogen also terminates P-II […]Read More